{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:29Z","timestamp":1792603109522,"version":"4.5.0"},"reference-count":78,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Special Research Fund for Talent Cultivation of the Second Affiliated Hospital of Xi\u2019an Jiaotong University","award":["RC(GG)202010"],"award-info":[{"award-number":["RC(GG)202010"]}]},{"award":["RC(GG)202010"],"award-info":[{"award-number":["RC(GG)202010"]}],"id":[{"id":"https:\/\/ror.org\/03aq7kf18","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Endobiliary photodynamic therapy (PDT) in cholangiocarcinoma (CCA) is used mainly for local palliation of malignant biliary obstruction, particularly in extrahepatic and perihilar disease. This Review synthesizes the clinical evidence on endobiliary PDT while using drainage, infection control, stent strategy, light delivery, and systemic-therapy context as an interpretive framework rather than as practice recommendations. This narrative review was informed by targeted searching of PubMed\/MEDLINE, Embase, and Web of Science from database inception through to 31 December 2025, supplemented by reference-list screening. We prioritized prospective studies, comparative cohorts, systematic reviews, and relevant guidance documents. Across the literature, the clearest support for PDT concerns selected local biliary palliation, including decompression, stent patency or delayed dysfunction, and symptom relief. Survival signals remain inconsistent: early positive studies contrast with the negative PHOTOSTENT-02 randomized trial and are highly confounded by drainage adequacy, infection control, retreatment strategy, and systemic-therapy access. We therefore interpret PDT as a context-dependent local biliary strategy rather than an established survival-prolonging treatment, and we highlight the clinical variables that make published outcome signals more or less interpretable.<\/jats:p>","DOI":"10.3390\/curroncol33060343","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:46:54Z","timestamp":1780998414000},"page":"343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endobiliary Photodynamic Therapy in Cholangiocarcinoma: Clinical Outcomes, Patient Selection, and Procedural Context"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2629-4240","authenticated-orcid":false,"given":"Xuewu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Pancreas and Liver Transplantation, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an 710006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreas and Liver Transplantation, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an 710006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1067\/mge.2001.113386","article-title":"Endoscopic application of photodynamic therapy for cholangiocarcinoma","volume":"53","author":"Rumalla","year":"2001","journal-title":"Gastrointest. Endosc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.5009\/gnl.2010.4.S1.S62","article-title":"Photodynamic Therapy for Cholangiocarcinoma","volume":"4","author":"Talreja","year":"2010","journal-title":"Gut Liver"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic therapy for cancer","volume":"3","author":"Dolmans","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","first-page":"250","article-title":"Photodynamic therapy of cancer: An update","volume":"61","author":"Agostinis","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jnci\/90.12.889","article-title":"Photodynamic Therapy","volume":"90","author":"Dougherty","year":"1998","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_9","first-page":"EVIDoa2200015","article-title":"Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM \u00c9vid."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.gastro.2003.07.015","article-title":"Successful photodynamic therapy for nonresectable cholangiocarcinoma: A randomized prospective study","volume":"125","author":"Ortner","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_11","first-page":"e000379","article-title":"PHOTOSTENT-02: Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer","volume":"3","author":"Pereira","year":"2018","journal-title":"ESMO Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/MCG.0000000000001524","article-title":"Photodynamic Therapy (PDT), Radiofrequency Ablation (RFA) with Biliary Stents in Palliative Treatment of Unresectable Extrahepatic Cholangiocarcinoma","volume":"56","author":"Mohan","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pdpdt.2012.03.002","article-title":"Photodynamic therapy for unresectable cholangiocarcinoma: A comparative effectiveness systematic review and meta-analyses","volume":"9","author":"Leggett","year":"2012","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02765099","article-title":"Implicit and explicit dosimetry in photodynamic therapy: A New paradigm","volume":"12","author":"Wilson","year":"1997","journal-title":"Lasers Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.21873\/anticanres.10995","article-title":"Photodynamic Therapy Using Novel Glucose-Conjugated Chlorin Increases Apoptosis of Cholangiocellular Carcinoma in Comparison with Talaporfin Sodium","volume":"36","author":"Murakami","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2169\/internalmedicine.54.4673","article-title":"Photodynamic Therapy Using Talaporfin Sodium for the Recurrence of Cholangiocarcinoma After Surgical Resection","volume":"54","author":"Shimizu","year":"2015","journal-title":"Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1055\/a-0659-9864","article-title":"Endoscopic biliary stenting: Indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline\u2014Updated October 2017","volume":"50","author":"Dumonceau","year":"2018","journal-title":"Endoscopy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/a-1075-4080","article-title":"ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"52","author":"Dumonceau","year":"2020","journal-title":"Endoscopy"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"ASGE Standards of Practice Committee, Khashab, M.A., Chithadi, K.V., Acosta, R.D., Bruining, D.H., Chandrasekhara, V., Eloubeidi, M.A., Fanelli, R.D., Faulx, A.L., and Fonkalsrud, L. (2015). Antibiotic prophylaxis for GI endoscopy. Gastrointest. Endosc., 81, 81\u201389.","DOI":"10.1016\/j.gie.2014.08.008"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"M\u00f6hring, C., Khan, O., Zhou, T., Sadeghlar, F., Mahn, R., Kaczmarek, D.J., Dold, L., Toma, M., Marinova, M., and Glowka, T.R. (2023). Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1227036"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/curroncol30020166","article-title":"Recent Updates on Local Ablative Therapy Combined with Chemotherapy for Extrahepatic Cholangiocarcinoma: Photodynamic Therapy and Radiofrequency Ablation","volume":"30","author":"Inoue","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Natha, C., Vemulapalli, V., and Thosani, N. (2025). Endoscopic Ablation in Cholangiocarcinoma. Cancers, 17.","DOI":"10.3390\/cancers17172843"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3748\/wjg.v23.i7.1278","article-title":"Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis","volume":"23","author":"Moole","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103318","DOI":"10.1016\/j.pdpdt.2023.103318","article-title":"Photodynamic therapy combined with systemic chemotherapy for unresectable extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"41","author":"Yu","year":"2023","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jhbp.512","article-title":"Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholangitis (with videos)","volume":"25","author":"Kiriyama","year":"2018","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/2050640615621235","article-title":"Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma","volume":"4","author":"Schmidt","year":"2016","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5946\/ce.2013.46.4.390","article-title":"Photodynamic Therapy in Unresectable Cholangiocarcinoma: Not for the Uncommitted","volume":"46","author":"Talreja","year":"2013","journal-title":"Clin. Endosc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5946\/ce.2021.274","article-title":"Comparing palliative treatment options for cholangiocarcinoma: Photodynamic therapy vs. radiofrequency ablation","volume":"55","author":"Mohammad","year":"2022","journal-title":"Clin. Endosc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.gie.2020.12.035","article-title":"ASGE guideline on the role of endoscopy in the management of malignant hilar obstruction","volume":"94","author":"Qumseya","year":"2021","journal-title":"Gastrointest. Endosc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.gie.2009.10.027","article-title":"A lexicon for endoscopic adverse events: Report of an ASGE workshop","volume":"71","author":"Cotton","year":"2010","journal-title":"Gastrointest. Endosc."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"On behalf of the EORTC Quality of Life Group, Friend, E., Yadegarfar, G., Byrne, C., Johnson, C.D., Sezer, O., Pucciarelli, S., Pereira, S.P., Chie, W.-C., and Banfield, A. (2011). Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br. J. Cancer, 104, 587\u2013592.","DOI":"10.1038\/sj.bjc.6606086"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/bjc.2016.284","article-title":"Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder","volume":"115","author":"Yadegarfar","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1477-2574.2011.00424.x","article-title":"Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma","volume":"14","author":"Cheon","year":"2012","journal-title":"HPB"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5009\/gnl.2014.8.3.318","article-title":"Long-Term Outcome of Photodynamic Therapy with Systemic Chemotherapy Compared to Photodynamic Therapy Alone in Patients with Advanced Hilar Cholangiocarcinoma","volume":"8","author":"Hong","year":"2014","journal-title":"Gut Liver"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1007\/s00464-020-08095-1","article-title":"Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma","volume":"35","author":"Li","year":"2020","journal-title":"Surg. Endosc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: From mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.redox.2021.102056","article-title":"Non-enzymatic lipid peroxidation initiated by photodynamic therapy drives a distinct ferroptosis-like cell death pathway","volume":"45","author":"Shui","year":"2021","journal-title":"Redox Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Segura-D\u00edaz, A., Stuckey, R., Florido, Y., Gonz\u00e1lez-Mart\u00edn, J.M., L\u00f3pez-Rodr\u00edguez, J.F., S\u00e1nchez-Sosa, S., Gonz\u00e1lez-P\u00e9rez, E., Perdomo, M.N.S., Perera, M.d.M., and de la Iglesia, S. (2020). Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A\/TET2\/ASXL1 Mutations. Cancers, 12.","DOI":"10.3390\/cancers12040934"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S34118","DOI":"10.1117\/1.JBO.30.S3.S34118","article-title":"Photodynamic therapy dosimetry: Current status and the emerging challenge of immune stimulation","volume":"30","author":"Wilson","year":"2025","journal-title":"J. Biomed. Opt."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s101030050047","article-title":"Monte Carlo Simulations of Light Distributions in an Embedded Tumour Model: Studies of Selectivity in Photodynamic Therapy","volume":"15","year":"2000","journal-title":"Lasers Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"083006","DOI":"10.1117\/1.JBO.27.8.083006","article-title":"Scalable and accessible personalized photodynamic therapy optimization with FullMonte and PDT-SPACE","volume":"27","author":"Wang","year":"2022","journal-title":"J. Biomed. Opt."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104058","DOI":"10.1016\/j.pdpdt.2024.104058","article-title":"Tools of clinical Photodynamic Therapy (PDT): A Mini Compendium","volume":"46","author":"Allison","year":"2024","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"123449","DOI":"10.1016\/j.ijpharm.2023.123449","article-title":"Profiling in-vitro release of verteporfin from VISUDYNE\u00ae liposomal formulation and investigating verteporfin binding to human serum albumin","volume":"646","author":"Siriwardane","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fahmy, S.A., Azzazy, H.M.E.-S., and Schaefer, J. (2021). Liposome Photosensitizer Formulations for Effective Cancer Photodynamic Therapy. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091345"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40265-024-02133-1","article-title":"Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma","volume":"85","author":"Brown","year":"2025","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"011502","DOI":"10.1063\/5.0244706","article-title":"Advances in nanotechnology for targeting cancer-associated fibroblasts: A review of multi-strategy drug delivery and preclinical insights","volume":"9","author":"Zhang","year":"2025","journal-title":"APL Bioeng."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhang, P.-J., Liu, M.-D., Fan, F.-Y., and Liu, K.-X. (2021). A Study on Mesoporous Silica Loaded with Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.665182"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41420-024-02236-4","article-title":"Advances in smart nanotechnology-supported photodynamic therapy for cancer","volume":"10","author":"Li","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijpharm.2013.06.035","article-title":"Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells","volume":"454","author":"Lee","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijpharm.2017.08.128","article-title":"Simple nanophotosensitizer fabrication using water-soluble chitosan for photodynamic therapy in gastrointestinal cancer cells","volume":"532","author":"Jeong","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00535-023-02054-y","article-title":"Induction of ferroptosis by photodynamic therapy and enhancement of antitumor effect with ferroptosis inducers","volume":"59","author":"Kojima","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Huang, Y.-P., Wang, Y.-X., Zhou, H., Liu, Z.-T., Zhang, Z.-J., Xiong, L., Zou, H., and Wen, Y. (2024). Surufatinib combined with photodynamic therapy induces ferroptosis to inhibit cholangiocarcinoma in vitro and in tumor models. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1288255"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/lsm.23857","article-title":"Study on the Synergistic Mechanism of Photodynamic Therapy Combined with Ferroptosis Inducer to Induce Ferroptosis in Cholangiocarcinoma","volume":"56","author":"Dong","year":"2024","journal-title":"Lasers Surg. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"104104","DOI":"10.1016\/j.pdpdt.2024.104104","article-title":"Photodynamic therapy inhibits cancer progression and induces ferroptosis and apoptosis by targeting P53\/GPX4\/SLC7A11 signaling pathways in cholangiocarcinoma","volume":"47","author":"Yan","year":"2024","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17474124.2022.2029700","article-title":"Identification of a ferroptosis-related gene signature for predicting the prognosis of cholangiocarcinoma","volume":"16","author":"Wang","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","article-title":"Ferroptosis, necroptosis, and pyroptosis in anticancer immunity","volume":"13","author":"Tang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/emboj.2011.497","article-title":"A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death","volume":"31","author":"Garg","year":"2012","journal-title":"EMBO J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s40425-019-0826-3","article-title":"Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine","volume":"7","author":"Turubanova","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: Past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Hua, J., Wu, P., Gan, L., Zhang, Z., He, J., Zhong, L., Zhao, Y., and Huang, Y. (2021). Current Strategies for Tumor Photodynamic Therapy Combined with Immunotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.738323"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Liu, X., Liu, X., Yu, J., Bai, X., Wu, X., Guo, X., Liu, Z., and Liu, X. (2022). Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.955920"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Tong, Q., Xu, J., Wu, A., Zhang, C., Yang, A., Zhang, S., Lin, H., and Lu, W. (2022). Pheophorbide A\u2013Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD\u2013L1 Expression. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112513"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eadg3840","DOI":"10.1126\/scitranslmed.adg3840","article-title":"The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets","volume":"16","author":"Sleeboom","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"104170","DOI":"10.3748\/wjg.v31.i11.104170","article-title":"Cholangiocarcinoma: The era of liquid biopsy","volume":"31","author":"Kotsifa","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107875","DOI":"10.5306\/wjco.v16.i10.107875","article-title":"Circulating tumor DNA in biliary tract cancers: A review of current applications","volume":"16","author":"Teixeira","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, Y., Liang, Z., Zhang, Y., Li, T., Tian, C., Zhao, J., Jin, B., Cao, J., and Lin, Y. (2025). Circulating tumor DNA in cholangiocarcinoma: Current clinical applications and future perspectives. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1616064"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1038\/s41598-025-96170-9","article-title":"Optimization of bile preparation for liquid biopsy in cholangiocarcinoma focusing on circulating tumor DNA and protein stability","volume":"15","author":"Han","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Almeida, J.L., Cole, K.D., and Plant, A.L. (2016). Standards for Cell Line Authentication and Beyond. PLoS Biol., 14.","DOI":"10.1371\/journal.pbio.1002476"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/343\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:28:02Z","timestamp":1781004482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060343"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060343","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}